{
  "ticker": "HPC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959996",
  "id": "02959996",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0949",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwzblzj2qxvl.pdf",
  "summary": "**Trading Update (Monthly Sales & Financials) - Key Points:**  \n- **May 2025 unaudited net sales:** US$308,000 (+34% MoM, +18% YoY), highest monthly sales in CY25.  \n- **Gross margin:** 66.5%, driven by high-margin SKUs.  \n- **EBITDA loss (unaudited):** US$127,000 (29% improvement vs April 2025); fifth consecutive month of improvement.  \n- **Cash balance (18 June 2025):** US$1.9m.  \n- **New SKUs:** Two launches planned in Q3 CY25 (gut/brain health segments).",
  "usage": {
    "prompt_tokens": 1481,
    "completion_tokens": 147,
    "total_tokens": 1628,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:57:35.214488"
}